首页> 外文OA文献 >Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker
【2h】

Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker

机译:通过体内质子磁共振光谱量量化多发性硬化的代谢特征:当前挑战和未来看法在诊断生物标志物的翻译中的翻译

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Proton magnetic resonance spectroscopy (1H-MRS) offers a growing variety of methods for querying potential diagnostic biomarkers of multiple sclerosis in living central nervous system tissue. For the past three decades, 1H-MRS has enabled the acquisition of a rich dataset suggestive of numerous metabolic alterations in lesions, normal-appearing white matter, gray matter, and spinal cord of individuals with multiple sclerosis, but this body of information is not free of seeming internal contradiction. The use of 1H-MRS signals as diagnostic biomarkers depends on reproducible and generalizable sensitivity and specificity to disease state that can be confounded by a multitude of influences, including experiment group classification and demographics; acquisition sequence; spectral quality and quantifiability; the contribution of macromolecules and lipids to the spectroscopic baseline; spectral quantification pipeline; voxel tissue and lesion composition; T1 and T2 relaxation; B1 field characteristics; and other features of study design, spectral acquisition and processing, and metabolite quantification about which the experimenter may possess imperfect or incomplete information. The direct comparison of 1H-MRS data from individuals with and without multiple sclerosis poses a special challenge in this regard, as several lines of evidence suggest that experimental cohorts may differ significantly in some of these parameters. We review the existing findings of in vivo1H-MRS on central nervous system metabolic abnormalities in multiple sclerosis and its subtypes within the context of study design, spectral acquisition and processing, and metabolite quantification and offer an outlook on technical considerations, including the growing use of machine learning, by future investigations into diagnostic biomarkers of multiple sclerosis measurable by 1H-MRS.
机译:质子磁共振波谱(1H-MRS)提供了越来越多的各种用于在活的中枢神经系统组织查询多发性硬化的潜在诊断性生物标记的方法。在过去的三个十年里,1H-MRS,使收购病变众多的代谢改变,正常表现脑白质,脑灰质,以及与多发性硬化症个体的脊髓丰富的数据集暗示,但这个机构的信息不释放似乎内在矛盾的。作为诊断性生物标记的用途1H-MRS信号的依赖于可重复和可普及敏感性和特异性,可以通过影响,包括实验组分类和人口统计的大量混淆疾病状态;采集序列;光谱质量和quantifiability;大分子和脂质光谱基线的贡献;谱定量管道;体素的组织和病变的组合物; T1和T2松弛; B1场特征;和研究设计,光谱采集和处理,以及代谢物的定量的其他的特征,其关于实验者可以具有不完全的或不完整的信息。从与不多发性硬化症的姿态在这方面具有特殊的挑战,因为一些证据个人1H-MRS数据的直接比较表明,实验组群可以在一些参数显著不同。我们回顾在研究设计,光谱采集和处理,以及代谢物定量范围内的多发性硬化症中枢神经系统代谢异常及其亚型vivo1H-MRS现有的调查结果,并提供技术考虑,其中包括越来越多地使用的前景机器学习,通过将来调查由1H-MRS多发性硬化可测量的诊断生物标志物。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号